Evry, January 17, 2012 -- Fulvio Mavilio, PhD (aged 58), an international acknowledged
expert and pioneer in gene therapy for rare diseases for more
than twenty years, was appointed as the new Scientific Director
of Généthon (the not-for-profit biotherapy lab funded by the
French Muscular Dystrophy Association (AFM) with donations
from France's annual Telethon) on January 1st, 2012. He
succeeds Philippe Moullier (Director of the INSERM 649 Viral
Vectors and in vivo Gene Transfer Unit in Nantes, France), who
had held the position since January 2009. Philippe Moullier
remains a special advisor to the management and will continue
his commitment to several of Généthon's scientific projects.
As a molecular biologist-geneticist by training, Fulvio Mavilio started to focus on
hematology and thus blood diseases in the early 1980s. In the 1990s, his work
gave rise to the worldwide first-in-man trial of stem cell gene therapy for the
treatment of a rare immunodeficiency (ADA-SCID). His belief in the long-term
value of gene therapy prompted him to co-found the San Raffaele Telethon
Institute for Gene Therapy (HSR-TIGET). He also cofounded the gene therapy
company GenEra S.p.A., who later merged into Molmed S.p.A. (a biotech
company specializing in innovative cancer therapies) where he served as Director
of R&D. He was also involved in setting up the University of Modena's Center for
Fulvio Mavilio commented that "Généthon is a world-famous benchmark
organization that offers unique opportunities in gene therapy for rare diseases.
With highly skilled, multidisciplinary research groups and Généthon BioProd (the
world largest facility for product gene-based drugs), joining Généthon constitutes
an extremely stimulating challenge!".
"We are delighted to welcome Fulvio to Généthon. His unique experience and
international stature constitute significant assets for developing Généthon-led
projects and making a success of the missions entrusted to us by Telethon
donors and the AFM" added Généthon Chief Executive Frédéric Revah. "I heartily
thank Philippe Moullier for his exception contribution over the last three years.
Généthon will continue to work closely with him in his new role".
Key dates in Fulvio Mavilio's career
1995: publication of the results of the gene therapy trial in ADA-SCID (a rare blood
1996: creation of the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET).
1997: publication of the results of the gene therapy trial for graft-versus-host disease (a
severe complication of bone marrow transplantation).
2006: publication of the results of the gene therapy trial for epidermolysis bullosa (a rare
2012 (January 1): appointed as Scientific Director of Généthon (Evry, France)
Created by the French Muscular Dystrophy Association (AFM), Généthon is funded almost
exclusively by donations from France's annual Telethon. Its goal is to deliver innovative
gene therapies to patients. After having played a pioneering role in deciphering the
human genome, with over 200 scientists, physicians, engineers and regulatory affairs
specialists, Généthon is one of the world's leading centers for preclinical and clinical
research and development in the field of gene therapy for rare diseases. Généthon also
has a biomanufacturing platform for clinical-grade vectors, that will open in Evry in 2012,
the world's largest facility for pre-industrial pilot production (Généthon BioProd).
About the AFM
The French Muscular Dystrophy Association (AFM) federates patients with neuromuscular
diseases (genetic diseases that kill, muscle after muscle) and their parents. Thanks in
great part to donations from France's annual Telethon (€90 million in 2010), the AFM has
become a major player in biomedical research into rare diseases in France and
worldwide. It is currently funding 36 clinical trials on 31 different genetic diseases
affecting the eyes, the blood, the brain, the immune system, the muscle... Thanks to its
Généthon research lab, the AFM stands out through its unique ability to produce and test
its own gene-based medicines.
More information at www.afm-telethon.fr
AFM – Généthon
Anne-Sophie Midol, Stéphanie Bardon, Géraldine Broudin
Tel.: +33 169 472 828 / +33 645 159 587 / email@example.com
Caroline Carmagnol – Mobile/Cellular: +33 664 189 959 / Tel.: +33 142 688 643 /
Anne-Sophie Cosquéric – Tel.: +33 142 688 641 – firstname.lastname@example.org